![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2022/10/03/2526655/0/en/Calithera-Receives-FDA-Fast-Track-Designation-for-Sapanisertib-for-the-Treatment-of-NRF2-mutated-Squamous-Lung-Cancer.html
https://www.globenewswire.com/news-release/2022/08/15/2498526/32478/en/Calithera-Biosciences-Reports-Second-Quarter-2022-Financial-Results-and-Recent-Highlights.html
https://www.globenewswire.com/news-release/2022/07/13/2479319/32478/en/Calithera-Biosciences-Shares-Progress-in-Sapanisertib-and-Mivavotinib-Clinical-Programs-at-Upcoming-Lung-Cancer-and-Lymphoma-Conferences.html
https://www.globenewswire.com/news-release/2022/07/06/2475432/32478/en/Calithera-Biosciences-Announces-First-Patient-Enrolled-in-Phase-2-Clinical-Trial-of-Sapanisertib-in-Relapsed-Refractory-NRF2-NFE2L2-Mutated-Squamous-Non-Small-Cell-Lung-Cancer.html
https://www.thepharmaletter.com/article/two-new-drugs-add-harmony-to-calithera-s-precision-pipeline?__cf_chl_jschl_tk__=pmd_x66vxwinkDHJdlA02hF8AvCwosLXtWK1gLCV4NmksrM-1634712524-0-gqNtZGzNApCjcnBszQs9